News
Current report No. 14/2022 – Supplementing the documentation for the Ordinary General Meeting of Celon Pharma S.A. convened to take place on June 22, 2022
Date prepared: June 15, 2022 Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: As a supplement to current report No. 13/2022 dated May 26, 2022 announcing the Ordinary General Meeting of Celon Pharma S.A. convened to take place on JuneRead more »
Current report No. 13/2022 – Notice on the convening of the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2022 with draft resolutions
Subject: Notice on the convening of the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2022 with draft resolutions Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: The Management Board of Celon Pharma S.A. (“the Company”), acting pursuantRead more »
Current report No. 12/2022 – The Management Board’s and the Supervisory Board’s recommendation on the coverage of loss for the year 2021 and payment of the dividend
Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. Date: May 25, 2021, 5:26 PM Content of the report: The Management Board of Celon Pharma S.A. (the “Company”) informs that on May 25, 2022 it adopted a resolution on recommendation for the Ordinary General Meeting of the Company onRead more »
Current report No. 11/2022 – Positive outcome of FDA’s assessment process of the IND application concerning the commencement of a clinical trial for Falkieri (Celon’s esketamine DPI)
Current report No. 11/2022Date prepared: 2022-23-05, at 4:14 pmAbbreviated name of the issuer: CELON PHARMA S.A. In connection with current report No. 9/2022 of 20 April 2022 on Celon Pharma S.A. (the “Company”) submitting an application to the Food and Drug Administration (FDA), the Management Board of the Company informs that today it has receivedRead more »
Current report no. 11/2022 – Positive outcome of FDA’s assessment process of the IND application concerning the commencement of a clinical trial for Falkieri (Celon’s esketamine DPI)
In connection with current report No. 9/2022 of 20 April 2022 on Celon Pharma S.A. (the “Company”) submitting an application to the Food and Drug Administration (FDA), the Management Board of the Company informs that today it has received information from the American regulatory authority that the Company may commence clinical trials of Falkieri (Celon’sRead more »
Celon Pharma at the #BIO2022 Convention
On 13-16 June this year, representatives of Celon Pharma will take part in this year’s BIO International Convention. This is the world’s largest meeting of representatives of the life industry, returning after the pandemic break in the classic formula. The participation of the company’s representatives is an expression of celon Pharma’s consistently implemented strategy ofRead more »
Celon Pharma joined the beneficiaries of the international project ORBIS – Open Research Biopharmaceutical Internships Support
The overall objective of the ORBIS project is to improve the development of innovative and generic medicines. The way to achieve this goal is the cooperation of representatives of academic institutions from various fields of pharmaceutical sciences and the research and development sector of companies. Therefore, the core of the project is the international exchangeRead more »
Current report No. 10/2022 – Submission of an application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon’s esketamine DPI) in treatment-resistant bipolar depression therapy
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on April 20, 2022 an application was submitted to the Food and Drug Administration (FDA) for the granting of the Breakthrough Designation to Falkieri (Celon’s esketamine DPI) in treatment-resistant bipolar depression therapy. This application is supported by results of pre-clinical and clinical trials,Read more »
Current report No. 9/2022 – Submission of an application to the Food and Drug Administration (FDA) concerning the commencement of a clinical trial for Falkieri (Celon’s esketamine DPI)
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on April 20, 2022 an application was submitted to the Food and Drug Administration (FDA) concerning the commencement of a clinical trial for Falkieri (Celon’s esketamine DPI) as a therapy for treatment-resistant bipolar depression under the so-called Investigational New Drug (IND) Application procedure.Read more »
Current report No. 8/2022 – Allocation of A series subscription warrants to eligible persons under the Incentive Program
Current report No. 8/2022Date prepared: 2022-04-15Abbreviated name of the issuer: CELON PHARMA S.A.Subject: Allocation of A series subscription warranties to eligible persons under the Incentive Program for persons of key importance to the CompanyLegal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.Content of the report:The Management Board of CelonRead more »